28 July 2021

Meet the Team - Rebecca Andersen

Introducing Rebecca Andersen

The fifth in our Meet the Team video series, which introduces some of the people who contribute to the important work of TauRx, is now available to view.

Rebecca Andersen, Market Access & Communications Manager, TauRx discusses what is inspirational about working for TauRx and the hope for the future of Alzheimer's disease treatment.

Look out for future Meet the Team videos! Watch Rebecca Andersen's video here or below.

More news

MHRA confirms acceptance of UK Marketing Authorisation Application for HMTM

TauRx submits UK marketing authorisation application for HMTM as a treatment for Alzheimer’s disease

Doctor examining MRI, MRT, CT scan image of human brain. Medical treatment concept. Diagnosis of the disease humans head. Close up.

Two year sustained cognitive benefits of Hydromethylthionine Mesylate (HMTM) indicated by TauRx’s LUCIDITY trial

Further reading

For decades, Professor Claude Wischik, co-founder and CEO of TauRx, has led a scientific research team dedicated to finding an effective treatment for neurodegenerative diseases.

Doctor or nurse caregiver with senior couple at home or nursing home

Clinical trials

TauRx recently completed its latest Phase III clinical trials in Alzheimer’s disease and in the rare neurodegenerative disorder, behavioural variant frontotemporal dementia (bvFTD).

Gears. Cog mechanism, engine system, operation progress, gear shift, industry innovation, engineering solution, technology concept.

Environmental, Social and Governance at TauRx

Maintaining integrity, accountability and transparency in our pursuit of life-changing treatments